These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 39005010)

  • 1. Interleukin-1 receptor 1 deficiency worsens hepatocellular carcinoma, while gemcitabine treatment alleviates the hepatocellular carcinoma-induced increase in intra-hepatic immune cells.
    Chu CS; Chen HP; Lin PH; Cheng CC; Kuo HY; Fan PH; Peng WH; Wu LL
    J Gastroenterol Hepatol; 2024 Oct; 39(10):2208-2218. PubMed ID: 39005010
    [TBL] [Abstract][Full Text] [Related]  

  • 2. IL-1β-Induced Elevation of Solute Carrier Family 7 Member 11 Promotes Hepatocellular Carcinoma Metastasis Through Up-regulating Programmed Death Ligand 1 and Colony-Stimulating Factor 1.
    He Q; Liu M; Huang W; Chen X; Zhang B; Zhang T; Wang Y; Liu D; Xie M; Ji X; Sun M; Tian D; Xia L
    Hepatology; 2021 Dec; 74(6):3174-3193. PubMed ID: 34288020
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Interactions between interleukin-6 and myeloid-derived suppressor cells drive the chemoresistant phenotype of hepatocellular cancer.
    Xu M; Zhao Z; Song J; Lan X; Lu S; Chen M; Wang Z; Chen W; Fan X; Wu F; Chen L; Tu J; Ji J
    Exp Cell Res; 2017 Feb; 351(2):142-149. PubMed ID: 28109867
    [TBL] [Abstract][Full Text] [Related]  

  • 4. IL-17 signaling in steatotic hepatocytes and macrophages promotes hepatocellular carcinoma in alcohol-related liver disease.
    Ma HY; Yamamoto G; Xu J; Liu X; Karin D; Kim JY; Alexandrov LB; Koyama Y; Nishio T; Benner C; Heinz S; Rosenthal SB; Liang S; Sun M; Karin G; Zhao P; Brodt P; Mckillop IH; Quehenberger O; Dennis E; Saltiel A; Tsukamoto H; Gao B; Karin M; Brenner DA; Kisseleva T
    J Hepatol; 2020 May; 72(5):946-959. PubMed ID: 31899206
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeting the crosstalk between cytokine-induced killer cells and myeloid-derived suppressor cells in hepatocellular carcinoma.
    Yu SJ; Ma C; Heinrich B; Brown ZJ; Sandhu M; Zhang Q; Fu Q; Agdashian D; Rosato U; Korangy F; Greten TF
    J Hepatol; 2019 Mar; 70(3):449-457. PubMed ID: 30414862
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hepatoma-intrinsic CCRK inhibition diminishes myeloid-derived suppressor cell immunosuppression and enhances immune-checkpoint blockade efficacy.
    Zhou J; Liu M; Sun H; Feng Y; Xu L; Chan AWH; Tong JH; Wong J; Chong CCN; Lai PBS; Wang HK; Tsang SW; Goodwin T; Liu R; Huang L; Chen Z; Sung JJ; Chow KL; To KF; Cheng AS
    Gut; 2018 May; 67(5):931-944. PubMed ID: 28939663
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Interleukin-21 receptor signaling promotes metabolic dysfunction-associated steatohepatitis-driven hepatocellular carcinoma by inducing immunosuppressive IgA
    Xie Y; Huang Y; Li ZY; Jiang W; Shi NX; Lu Y; Cao G; Yin Z; Lin XJ
    Mol Cancer; 2024 May; 23(1):95. PubMed ID: 38720319
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Plasma Cell Polarization to the Immunoglobulin G Phenotype in Hepatocellular Carcinomas Involves Epigenetic Alterations and Promotes Hepatoma Progression in Mice.
    Wei Y; Lao XM; Xiao X; Wang XY; Wu ZJ; Zeng QH; Wu CY; Wu RQ; Chen ZX; Zheng L; Li B; Kuang DM
    Gastroenterology; 2019 May; 156(6):1890-1904.e16. PubMed ID: 30711627
    [TBL] [Abstract][Full Text] [Related]  

  • 9. ABL1, Overexpressed in Hepatocellular Carcinomas, Regulates Expression of NOTCH1 and Promotes Development of Liver Tumors in Mice.
    Wang F; Hou W; Chitsike L; Xu Y; Bettler C; Perera A; Bank T; Cotler SJ; Dhanarajan A; Denning MF; Ding X; Breslin P; Qiang W; Li J; Koleske AJ; Qiu W
    Gastroenterology; 2020 Jul; 159(1):289-305.e16. PubMed ID: 32171747
    [TBL] [Abstract][Full Text] [Related]  

  • 10. SPTBN1 inhibits inflammatory responses and hepatocarcinogenesis via the stabilization of SOCS1 and downregulation of p65 in hepatocellular carcinoma.
    Lin L; Chen S; Wang H; Gao B; Kallakury B; Bhuvaneshwar K; Cahn K; Gusev Y; Wang X; Wu Y; Marshall JL; Zhi X; He AR
    Theranostics; 2021; 11(9):4232-4250. PubMed ID: 33754058
    [No Abstract]   [Full Text] [Related]  

  • 11. Hepatocellular Carcinoma Cells Up-regulate PVRL1, Stabilizing PVR and Inhibiting the Cytotoxic T-Cell Response via TIGIT to Mediate Tumor Resistance to PD1 Inhibitors in Mice.
    Chiu DK; Yuen VW; Cheu JW; Wei LL; Ting V; Fehlings M; Sumatoh H; Nardin A; Newell EW; Ng IO; Yau TC; Wong CM; Wong CC
    Gastroenterology; 2020 Aug; 159(2):609-623. PubMed ID: 32275969
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Gemcitabine-facilitated modulation of the tumor microenvironment and PD-1/PD-L1 blockade generate a synergistic antitumor effect in a murine hepatocellular carcinoma model.
    Wang H; He X; Fang D; Wang X; Guan J; Shi ZW; Chen X
    Clin Res Hepatol Gastroenterol; 2022 Apr; 46(4):101853. PubMed ID: 34923183
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A novel spontaneous hepatocellular carcinoma mouse model for studying T-cell exhaustion in the tumor microenvironment.
    Liu YT; Tseng TC; Soong RS; Peng CY; Cheng YH; Huang SF; Chuang TH; Kao JH; Huang LR
    J Immunother Cancer; 2018 Dec; 6(1):144. PubMed ID: 30526672
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeting monocyte-intrinsic enhancer reprogramming improves immunotherapy efficacy in hepatocellular carcinoma.
    Liu M; Zhou J; Liu X; Feng Y; Yang W; Wu F; Cheung OK; Sun H; Zeng X; Tang W; Mok MTS; Wong J; Yeung PC; Lai PBS; Chen Z; Jin H; Chen J; Chan SL; Chan AWH; To KF; Sung JJY; Chen M; Cheng AS
    Gut; 2020 Feb; 69(2):365-379. PubMed ID: 31076403
    [TBL] [Abstract][Full Text] [Related]  

  • 15. IL-6 and PD-L1 blockade combination inhibits hepatocellular carcinoma cancer development in mouse model.
    Liu H; Shen J; Lu K
    Biochem Biophys Res Commun; 2017 Apr; 486(2):239-244. PubMed ID: 28254435
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Regulation of accumulation and function of myeloid derived suppressor cells in different murine models of hepatocellular carcinoma.
    Kapanadze T; Gamrekelashvili J; Ma C; Chan C; Zhao F; Hewitt S; Zender L; Kapoor V; Felsher DW; Manns MP; Korangy F; Greten TF
    J Hepatol; 2013 Nov; 59(5):1007-13. PubMed ID: 23796475
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hepatic Stellate Cells Enhance Liver Cancer Progression by Inducing Myeloid-Derived Suppressor Cells through Interleukin-6 Signaling.
    Hsieh CC; Hung CH; Chiang M; Tsai YC; He JT
    Int J Mol Sci; 2019 Oct; 20(20):. PubMed ID: 31614930
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Icaritin-induced immunomodulatory efficacy in advanced hepatitis B virus-related hepatocellular carcinoma: Immunodynamic biomarkers and overall survival.
    Qin SK; Li Q; Ming Xu J; Liang J; Cheng Y; Fan Y; Jiang J; Ye H; Tao H; Li L; Zheng L; Wei Z; Li S; Meng K; Ye B; Sun Y
    Cancer Sci; 2020 Nov; 111(11):4218-4231. PubMed ID: 32889778
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hepatic carcinoma-associated fibroblasts enhance immune suppression by facilitating the generation of myeloid-derived suppressor cells.
    Deng Y; Cheng J; Fu B; Liu W; Chen G; Zhang Q; Yang Y
    Oncogene; 2017 Feb; 36(8):1090-1101. PubMed ID: 27593937
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Interleukin 1β-mediated HOXC10 Overexpression Promotes Hepatocellular Carcinoma Metastasis by Upregulating PDPK1 and VASP.
    Dang Y; Chen J; Feng W; Qiao C; Han W; Nie Y; Wu K; Fan D; Xia L
    Theranostics; 2020; 10(8):3833-3848. PubMed ID: 32206125
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.